Literature DB >> 12098107

IV. Uterine fibroid embolization: follow-up.

John C Lipman1, Steven J Smith, James B Spies, Gary P Siskin, Lindsay S Machan, Joseph Bonn, Robert L Worthington-Kirsch, Scott C Goodwin, David M Hovsepian.   

Abstract

Patients generally notice some relief of both menorrhagia and mass-effect symptoms during the first few weeks after uterine fibroid embolization (UFE). Shrinkage of the fibroids continues to take place over several months, peaking somewhere between 3 and 6 months, with measurable shrinkage sometimes noted for up to 1 year. The timing of follow-up visits is intended to coincide with the time course of improvement so that diagnostic imaging and intervention can be performed if symptoms worsen or relief does not appear to be on schedule. The amount of shrinkage of fibroids correlates neither with the intensity of immediate postprocedure symptoms or the degree of symptom relief. Affected fibroids undergo hyaline degeneration, a process in which the hard, cellular tumor is replaced by softer, acellular material. A nationwide registry has been constructed for the accumulation of procedural and follow-up data so that success and complication rates can be accurately determined and long-term issues about the durability of UFE and possible side effects can be addressed. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12098107     DOI: 10.1053/tvir.2002.124102

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  2 in total

Review 1.  [Risk and complication rate of uterine fibroid embolization (UFE)].

Authors:  B Radeleff; S Rimbach; G W Kauffmann; G M Richter
Journal:  Radiologe       Date:  2003-08       Impact factor: 0.635

2.  Effectiveness of intra-arterial anesthesia for uterine fibroid embolization using dilute lidocaine.

Authors:  Songhua Zhan; Yi Li; Guoliang Wang; Hongjie Han; Zhenyan Yang
Journal:  Eur Radiol       Date:  2005-02-05       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.